Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Renalytix AI ( (GB:RENX) ) has shared an announcement.
Renalytix has provided a trading update indicating that it remains on track to meet its financial targets for the fiscal years 2025 and 2026, supported by a significant increase in the number of tests ordered and a successful £11.8m funding round. The company expects to report revenues of $1.3 million for the first half of fiscal year 2025, with continued growth driven by new partnerships and increased sales representative productivity. The expansion includes onboarding a large New York-based primary care network, which has bolstered growth and is expected to encourage further adoption of kidneyintelX.dkd in the coming year.
More about Renalytix AI
Renalytix is an artificial intelligence-enabled in vitro diagnostics company focused on improving clinical management of kidney disease. The company has developed kidneyintelX.dkd, the only FDA-approved and Medicare reimbursed prognostic test for early-stage risk assessment of chronic kidney disease, which is commercially available in the United States. This tool is designed to aid in the diagnosis, prognosis, and treatment of kidney disease, significantly impacting patient outcomes by allowing for early intervention.
YTD Price Performance: 103.75%
Average Trading Volume: 1,400
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $46.39M
See more insights into RENX stock on TipRanks’ Stock Analysis page.
